Loading...
Market
What will be the primary benefit of machine-learning models for monoclonal antibody allocation by December 31, 2025?
2
Resolution / Starting Odds
Reduction in hospital cases • 25%
Efficient resource allocation • 25%
Improved patient outcomes • 25%
Other • 25%
Research publications or official healthcare reports
Story
Researchers Develop Monoclonal Antibodies Against A. baumannii to Combat Antimicrobial Resistance
Sep 17, 2024, 09:00 AM
Researchers are exploring the use of monoclonal antibodies as a potential solution to tackle antimicrobial resistance, which could make infections untreatable in the future. Scientists at Cambridge University, including those at the Baker Lab, have developed monoclonal antibodies that show effectiveness against drug-resistant infections, specifically using engineered mice against A. baumannii. Prof. Stephen Baker highlighted the potential of this approach as a powerful new weapon. Additionally, machine-learning models for monoclonal antibody allocation during pandemics could reduce hospital cases by a third by targeting at-risk patients and those who would benefit most from treatments. This method may also alleviate reliance on broad-spectrum antimicrobials for treating infections.
View original story
Similar markets
University of Michigan • 25%
EPFL • 25%
MIT • 25%
Other • 25%
University of Michigan's AI tool • 25%
AlphaFold-Multimer • 25%
EPFL's RENAISSANCE • 25%
Other • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Accuracy • 25%
Speed • 25%
Scalability • 25%
Cost-effectiveness • 25%
Improved data infrastructure • 33%
Enhanced program tracking • 33%
Accelerated healthcare innovation • 33%
Neurology • 25%
Oncology • 25%
Cardiology • 25%
Other • 25%
Improved diagnostic accuracy • 25%
Reduced administrative workload • 25%
Addressed staffing shortages • 25%
Enhanced patient management • 25%
Cancer treatment • 25%
Neurodegenerative disease treatment • 25%
Cardiovascular disease treatment • 25%
Other • 25%
Reduction in hallucinations • 25%
Improvement in factual accuracy • 25%
Enhanced numerical and statistical data integration • 25%
Other • 25%
Cancer treatment • 25%
Infectious diseases • 25%
Neurological disorders • 25%
Other • 25%
Drug Discovery • 25%
Agricultural Biotechnology • 25%
Personalized Medicine • 25%
Other • 25%